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Abstract
Introduction: The management of suspected central venous catheter (CVC)-related sepsis by guide wire exchange
(GWX) is not recommended. However, GWX for new antimicrobial surface treated (AST) triple lumen CVCs has
never been studied. We aimed to compare the microbiological outcome of triple lumen AST CVCs inserted by
GWX (GWX-CVCs) with newly inserted triple lumen AST CVCs (NI-CVCs).
Methods: We studied a cohort of 145 consecutive patients with GWX-CVCs and contemporaneous site-matched
control cohort of 163 patients with NI-CVCs in a tertiary intensive care unit (ICU).
Results: GWX-CVC and NI-CVC patients were similar for mean age (58.7 vs. 62.2 years), gender (88 (60.7%) vs. 98
(60.5%) male) and illness severity on admission (mean Acute Physiology and Chronic Health Evaluation (APACHE) III:
71.3 vs. 72.2). However, GWX patients had longer median ICU lengths of stay (12.2 vs. 4.4 days; P < 0.001) and
median hospital lengths of stay (30.7 vs. 18.0 days; P < 0.001). There was no significant difference with regard to
the number of CVC tips with bacterial or fungal pathogen colonization among GWX-CVCs vs. NI-CVCs (5 (2.5%) vs.
6 (7.4%); P = 0.90). Catheter-associated blood stream infection (CA-BSI) occurred in 2 (1.4%) GWX patients
compared with 3 (1.8%) NI-CVC patients (P = 0.75). There was no significant difference in hospital mortality (35
(24.1%) vs. 48 (29.4%); P = 0.29).
Conclusions: GWX-CVCs and NI-CVCs had similar rates of tip colonization at removal, CA-BSI and mortality. If the
CVC removed by GWX is colonized, a new CVC must then be inserted at another site. In selected ICU patients at
higher central vein puncture risk receiving AST CVCs GWX may be an acceptable initial approach to line insertion.
Keywords: central venous catheters, catheter related blood stream infection, sepsis, bacteraemia, intensive care,
Gram negative bacteria
Introduction
Central venous catheters (CVCs) are commonly used in
intensive care units. However, their use is not without
risk [1-3] and line-related bacteraemia and sepsis remain
significant problems [4-6]. Several studies in the 1990s
suggested that regular line change does not decrease the
risk of line-related sepsis and exposes patients to the
risks associated with a new insertion (pneumothorax
and arterial puncture) [7-9]. Thus, in the absence of
clear identification of an alternative source of sepsis,
clinicians currently respond to signs of possible or sus-
pected CVC infection (new fever, increased white cell
count, increased C-reactive protein or procalcitonin
levels or a combination of these indicators) [10-12] by
removing the CVC as the possible infective source
[13,14]. However, if a CVC continues to be required, the
removed CVC can then be replaced by two techniques:
either by inserting a new CVC at another site or by
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inserting the new CVC at the same site by guide wire
exchange (GWX) [9-15]. Finally, if GWX is performed
and the tip of the line so removed grows a pathogen,
the CVC inserted by GWX is removed and a fresh CVC
is inserted at another site.
Theoretically, a new CVC insertion at a new site
exposes the patient to some risk of arterial or lung
puncture while, logically, GWX will eliminate the risk
associated with such a puncture [16-19]. However,
GWX may expose patients to a greater risk of line con-
tamination through inadequate protection of the inser-
tion field with anti-bacterial solutions. This, in turn,
could potentially increase the risk of subsequent line tip
colonization and bacteraemia [20-23]. Regrettably,
despite the relatively common occurrence of suspected
line related sepsis and the importance of this issue in
daily practice, little empirical data exist to guide clinical
practice.
The last decade has seen the widespread introduction
of antimicrobial surface treated (AST) CVCs [24-27].
These AST-CVCs are associated with less line-related
colonization and sepsis [26,27]. These CVCs may be
logically expected to also diminish the risk of infection
associated with GWX. Yet, to our knowledge, no studies
have compared the risk of line colonization with patho-
gens and/or catheter-associated bloodstream infection
(CA-BSI) when such surface treated CVCs are inserted
by GWX. Accordingly, we conducted a retrospective
study and estimated the incidence of subsequent line
colonization and CA-BSI after GWX of AST-CVCs
compared with a matched cohort of newly inserted
AST-CVCs. We aimed to test the hypothesis that the
incidence of CVC colonization with pathogens would
still be much greater with GWX insertion.
Materials and methods
This study was approved by the Austin Hospital Human
Research Ethics Committee (HREC). The Austin HREC
waived the need for informed consent for this study
because it involved no intervention and the use of routi-
nely collected data which were also de-identified and
made anonymous for the purpose of the investigation.
Our unit has exclusively used antimicrobial surface
treated (chlorhexidine acetate and silver sulfadiazine) tri-
ple lumen CVCs (Arrowgard blue®, Arrow-Howes,
Reading, PA, USA) since 2005. Thus, we conducted a
retrospective study of all CVCs inserted in our ICU as
consecutively recorded in our database since 2005.
All line insertion-related data are recorded prospec-
tively in our database as part of an ongoing quality
assurance process whenever an ICU doctor inserts a
CVC, arterial line, dialysis catheter or other invasive
lines. The database contains specific information regard-
ing when the CVC was inserted, the reason and method
of insertion, any complications and the reason and tim-
ing of removal.
We used this database to identify all patients who had
a central line inserted by GWX and selected a control
population. Controls were selected as the patients in the
database who had a new CVC inserted in ICU but not
by the GWX method on the same day or as close to the
same day as possible and, whenever possible, at the
same site. This matching approach was selected because
the average time to GWX of a CVC was seven days
after admission and matching by admission to character-
istics did not appear logical. On the other hand, match-
ing controls for date of CVC insertion was considered
to decrease the more relevant risks of CVC-insertion
doctor and time-related bias.
We excluded patients who had a new CVC inserted
(non-GWX) within 72 hours of a GWX, to avoid possi-
ble difficulties in attributing any source of bacteraemia.
The decision to perform a GWX insertion in the pre-
sence of suspected CVC infection was made by the
treating clinician in consideration of all possible risks
and benefits of such an approach following unit protocol
(see below).
Approach to suspected line infection
During the study period, the approach to suspected line
infection followed these unit guidelines:
1. Consider line infection if there is: a) a new fever
or worsening fever not explained by likely infection
elsewhere; b) an elevated white cell count or worsen-
ing white cell count not explained by likely infection
elsewhere.
2. If line infection is suspected, inspect the insertion
site. If there is redness or any suspicion of site infec-
tion, remove the line and insert a new CVC else-
where. If there is no evidence of skin inflammation,
consider the risks and benefits of GWX vs. new line
insertion elsewhere.
3. If the patient has coagulopathy, thrombocytopenia,
marked obesity, lack of other suitable sites for CVC
insertion or other anatomical features that make
new line insertion relatively contraindicated, proceed
to GXW.
4. In all cases, send the line of the suspected tip for
culture and obtain blood cultures, urine cultures and
sputum cultures.
5. If GWX has been completed and the line tip of
the removed CVC is subsequently found to be colo-
nized, remove the GWX CVC and insert a new CVC
elsewhere.
6. If a CVC is removed because it is no longer
needed and there is no clinical suspicion of infec-
tion, do not send the tip for culture.
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Patients with shock (vasopressor dependence) were
excluded as they required continued infusion of vaso-
pressors, which could not be maintained during the
GWX of the line.
We then obtained data on CVC tip cultures for both
the GWX and control groups using the hospital micro-
biology database, as well as blood cultures taken during
the time the line was in situ and for 48 hours after line
removal.
Once the intervention and control groups had been
identified, we compared the two groups for patient char-
acteristics as obtained by the ICU admissions and dis-
charges database, which is part of the Australian and
New Zealand adult patient database program [28]. Such
data included age, sex, admission diagnosis, Acute Phy-
siology and Chronic Health Evaluation (APACHE) III
score, use of mechanical ventilation and key outcomes.
Similarly, we compared the two groups for microbiologi-
cal outcomes including: a) the number of CVC tips that
were sent for culture, b) the number which had a posi-
tive tip culture for a pathogen (exclusion of skin flora
and skin commensal organisms unless isolated from two
different blood cultures as per Centre for Disease Con-
trol guidelines), and c) the number of patients who had
catheter-associated blood stream infection (CA-BSI)
using the criteria described by the US National Nosoco-
mial Infections Surveillance System of the Centers for
Disease Control and Prevention as used in a recent mul-
ticentre study [29]. Finally, we compared patient out-
comes. For this comparison, we assessed the patients’
length of stay in the ICU, the length of stay in hospital,
and their survival status at ICU and hospital discharge.
Technique of guide wire exchange (GWX)
Since 1995, the technique employed at our institution
for changing CVCs over a guide wire involves full asep-
tic precautions (gloves, gown, hat and mask). The steps
used to insert the line by GWX are shown in a photo-
graphic sequence using a mannequin from Figure 1a-i.
In brief, the patient is positioned as for a new CVC
insertion. Approximately 5 cm of the catheter external
to the entry site are extensively prepared with chlorhexi-
dine solution in 70% alcohol solution. Some parts of the
catheter are more difficult to cover with the antiseptic
solution. These, including the hub and connecting ports,
are covered with drapes, which are later removed.
The skin surrounding the catheter insertion site is also
treated with an alcohol and chlorhexidine solution, and
sterile drapes are placed appropriately to cover the
catheter except for the component under manipulation.
The segment of catheter remaining uncovered is then
covered with alcohol-chlorhexidine impregnated gauze.
The catheter is clamped just above its point of entry in
the skin and, using sterile scissors, the CVC is then cut
below the hub and 3 to 4 cm from the skin. The exter-
nal cut portion is covered with drapes. The operator
then removes his/her gloves and changes to a new pair
of sterile gloves.
The field is further covered so that only a small skin
surface of 3 to 5 cm2 is exposed where the CVC enters
the skin. The severed cross-section of the line shows the
various lumens and the soft J tip of the guide wire is
then inserted into the largest lumen (distal 16 gauge
lumen) until it meets the resistance of the clamp. The
clamp is removed with one hand, while the other holds
the external part of the CVC.
The wire is then advanced to 20 cm and the ‘old’ CVC
is removed over it. The removed CVC is placed onto the
sterile drapes, the distal 5 cm portion is cut with sterile
scissors, placed in a sterile container and sent for subse-
quent microbiological culture. The operator now has a
wire in place for a new central line insertion. A new
catheter can now be inserted over the wire and secured
to the skin as would be the case for a new CVC.
All lines are inserted by a variable group of doctors
(residents, fellows, specialists) during the study period. If
junior doctors inserted the catheter, it is under supervi-
sion of a senior doctor.
Skin preparation is with 2% chlorhexidine in 70% alco-
hol. Protection of the CVC site after insertion is in the
form of a “sandwich” cover with a transparent dressing
(IV 300 Frame Delivery, Smith & Nephew, Hull, UK) and
with a chlorhexidine impregnated antimicrobial disk
(Biopatch, Ethicon Inc., Bridgewater, NJ, USA) around
the skin entry site (Figure 2). The dressing is not changed
until line removal; nursing care is given on a 1:1 ratio to
all patients with no regular change to giving sets.
Line removal is decided upon by the treating clinicians
with consideration of all relevant aspects of patient
management.
Microbiological methods
In our microbiology lab, CVC tips are processed by first
adding 2 ml of D/E Neutralizing Broth (Neogen, Lan-
sing, MI, USA) to neutralize any residual disinfectants
or antimicrobials. The tip and broth are vortexed for 30
seconds, then 100 μL of the fluid are inoculated onto a
horse blood agar plate (BioMerieux, Marcy-l’Etoile,
France). Plates are incubated at 36°C in a 5% CO2 incu-
bator, and read at 24 and 48 hours. Any positive cul-
tures are subsequently identified by routine laboratory
methods, and reported as qualitative cultures only.
Blood samples are collected in aerobic and anaerobic
bottles for culture (Bactec 9240, Becton Dickinson,
Sparks, MD, USA), and cultured for five days. Positive
bottles are then sub-cultured manually onto HBA, cho-
colate HBA and anaerobic HBA (plus Sabaraud dextrose
agar if yeasts present in Gram stain) (BioMerieux), and
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incubated aerobically, anaerobically and in 5% CO2 for
up to five days. Positive cultures are subsequently identi-
fied according to routine laboratory methods.
Statistical analysis
All analyses are performed using SAS version 9.2 (SAS
Institute Inc., Cary, NC, USA). Group comparisons are
made using chi-square tests for equal proportions of
Fisher’s exact test when appropriate for categorical data,
Student’s t-test and Wilcoxon rank sum test for contin-
uous data. Results are reported as numbers (percen-
tages), means (standard deviation) or medians
(interquartile range) as appropriate. Due to the low
number of outcomes, multivariable logistic regression
was not performed. A two-sided P-value of 0.05 was
considered to be statistically significant.
Figure 1 Illustration of the sequence for the guide wire exchange of central venous catheter. (a) Approximately 5 cm of the catheter
external to the entry site are extensively prepared with chlorhexidine solution in 70% alcohol solution. Some parts of the catheter are more
difficult to cover with the antiseptic solution. These, including the hub and connecting ports, are covered with drapes and later removed. (b)
The skin surrounding the catheter insertion site is also treated with an alcohol and chlorhexidine solution, and sterile drapes are placed
appropriately to cover the catheter except for the component under manipulation. The segment of catheter remaining uncovered is then
covered with alcohol-chlorhexidine impregnated gauze. (c) The catheter is clamped just above its point of entry in the skin and, using sterile
scissors. (d) The CVC is cut below the hub and 3 to 4 cm from the skin. (e) The external cut portion is covered with drapes. The operator then
removes his/her gloves and changes to a new pair of sterile gloves. The field is further covered so that only a small skin surface of 3 to 5 cm2 is
exposed where the CVC enters the skin. (f) The severed cross section of the line shows the various lumens and the soft J tip of the guide wire is
then inserted into the largest lumen (distal 16 gauge lumen) until it meets the resistance of the clamp. The clamp is removed with one hand,
while the other holds the external part of the CVC. The wire is then advanced to 20 cm and the ‘old’ CVC is removed over it. (g) The operator
now has a wire in place for a new central line insertion. (h) The removed CVC is placed on to the sterile drapes, the distal 5 cm portion is cut
with sterile scissors, placed in a sterile container and set for subsequent microbiological culture. (i) A new catheter can now be inserted over the
wire and secured to the skin as would be the case for a new CVC.
Parbat et al. Critical Care 2013, 17:R184
http://ccforum.com/content/17/5/R184
Page 4 of 9
Results
We compared microbiological data from the 145
patients with a GWX-CVC insertion with those of 163
control patients with a NI-CVC from December 2005 to
February 2011 (Table 1). During this time a total of
2,378 CVCs were inserted in the unit. At the time of
CVC insertion, all patients receiving GWX have sus-
pected line infection. All lines replaced by GWX were
sent for cultures and blood cultures were obtained. The
line tips of the CVC removed by GWX grew coagulase
negative staphylococci in 11 cases, enterococci in 1,
gram negative bacilli in 1 and Candida albicans in 1. In
all cases, the newly inserted GWX line was removed
and a new CVC placed elsewhere. In two additional
cases, both blood culture and CVC tip grew the same
organisms (Klebsiella and Candida albicans). In both
cases, the newly inserted GWX CVC was removed and
a new CVC placed elsewhere.
Both groups were similar for gender distribution,
mean age and APACHE III scores on admission. There
was also no significant difference in APACHE III admis-
sion-related diagnostic groups and co-morbidities.
Figure 2 Illustration of central venous catheter insertion site
care and cover Skin preparation was with 2% chlorhexidine in
70% alcohol. Protection of the CVC site after insertion was in the
form of a “sandwich” cover with a transparent dressing (IV 300
Frame Delivery, Smith & Nephew, Hull, UK) and with a chlorhexidine
impregnated antimicrobial disk (Biopatch, Bridgewater, Ethicon Inc.,
NJ, USA) around the skin entry site.
Table 1 Study patients’ characteristics at ICU admission
Total (n = 308) Controls (n = 163) GWX (n = 145) P
Sex Male 186 (60%) 98 (60%) 88 (61%) 0.92
Age Mean (SD) 60.6 (16.4) 62.21 (15.6) 58.7 (17.1) 0.07
Diagnosis at admission Respiratory 40 (13%) 24 (15%) 16 (11%) 0.33
Hepatic 25 (8.1%) 12 (7%) 13 (9%) 0.60
Cardiac 77 (25%) 44 (14.3%) 33 (23%) 0.39
GI 43 (14%) 23 (27%) 20 (14%) 0.93
Hematological 5 (1.6%) 1 (0.6%) 4 (3%) 0.19
Neurological 33 (10.7%) 23 (27%) 10 (7%) 0.04
Metabolic 6 (2%) 4 (2.5%) 2 (1%) 0.68
Sepsis 40 (13%) 29 (18%) 11 (8%) 0.01
Renal 12 (4%) 4 (2.5%) 8 (6%) 0.23
Vascular 10 (3.25%) 5 (3%) 5 (3%) 0.85
Trauma 16 (5.2%) 4 (2.5%) 12 (8%) 0.36
Musculoskeletal 1 (0.3%) 1 (0.6%) 0 (0%) 0.99
Apache III scores Mean (SD) 71.8 (13.6) 72.3 (30.44) 71.3 (30.8) 0.77
Co-morbidities
Immune disease 31 (10%) 20 (12%) 12 (8%) 0.26
Immuno-suppression 28 (9%) 12 (7%) 15 (10%) 0.35
Chronic liver disease 25 (8%) 13 (8%) 11 (8%) 0.91
Metastases 12 (4%) 9 (6%) 4 (3%) 0.23
Leukaemia/myeloma/lymphoma 9 (3%) 6 (4%) 4 (3%) 0.14
Hepatic failure 12 (4%) 6 (4%) 5 (3%) 0.92
IDDM 0 (0%) 6 (4%) 2 (1%) 0.21
Chronic respiratory disease 3 (1%) 0 (0%) 2 (1%) 0.22
Cardiovascular disease 12 (4%) 4 (2%) 8 (6%) 0.16
Chronic renal failure 18 (6%) 12 (7%) 6 (4%) 0.23
GWX, guide wire exchange; IDDM, Insulin-Dependent Diabetes Mellitus
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However, 134 (92.4%) patients in the GWX group were
mechanically ventilated compared with 127 (77.9%) in
the control group (P = 0.005). There were no complica-
tions of GWX insertion. In the control group, there
were two episodes of arterial puncture which required
manual compression with one residual haematoma.
There were no pneumothoraces. Microbiological data
are presented in Table 2.
As expected given a period of pre-GWX cannulation,
there was a significant difference in ICU length of stay
between the two study groups. The GWX group had a
longer ICU length of stay than the control group (med-
ian (IQR) of 12.2 (4.8 to 17.8) days compared to 4.4 (2.1
to 9.0) days in the control group; P < 0.001. This signifi-
cant difference persisted for hospital length of stay with
a median for the GWX group of 30.7 (17.3 to 56.7) days
compared with 18.0 (8.5 to 37.7) days for the control
group (P < 0.001). Median time from insertion to dis-
charge from ICU was 5 (2 to 10) vs. 3 (2 to 7) days for
the GWX and control group, respectively (P = 0.005);
while time from insertion to hospital discharge was 19
(10 to 42) vs. 13 days (5 to 31) (P = 0.003).
The most common site for line insertion was the
internal jugular vein in both groups (91 (62.7%) in the
GWX group, vs. 96 (58.9%) in the control group; P =
0.49) followed by the femoral vein (25 (17.2%) in the
GWX group vs. 42 (25.7%) in the control group; P =
0.07) and finally, the subclavian vein (8 (5.5%) in the
GWX group vs. 9 (5.5%) in the control group; P = 0.99]
Tip cultures from the CVC were obtained in 81
(55.9%) GWX patients and in 95 (58.3%) of controls
(P = 0.66). Pathogens were isolated from six (6.3%; 95%
CI: 1.7 to 10.9) tips (three Gram negative organisms,
two Staphylococcus isolates and one Candida) in six
control patients compared with five (5.9%; 95% CI: 1.9
to 9.9%) tips in five GWX patients (five Gram negative
isolates) (Table 2).
For the 13 patients who had a positive CVC tip cul-
ture and a positive blood culture during their ICU stay,
the same organism was isolated in both cultures in two
patients in the GWX group vs. three patients in the
control group (Table 2). The overall incidence of CA-
BSI was 2.6 events/1,000 catheter days (1.8 (0 to 5) for
GWX vs. 3.5 (0 to 14) for controls. There was no
significant difference between the two groups for ICU
mortality (19 (13.1%) vs. 31 (19.0%); P = 0.15) and hos-
pital mortality (35 (24.1%) vs. 48 (29.4%); P = 0.29).
Discussion
Key findings
In a clinical environment where all CVCs inserted are
antimicrobial surface treated (AST) CVCs, we con-
ducted a retrospective observational study to test the
hypothesis that GWX would result in a major
increased incidence of subsequent line colonization
with pathogens compared with NI-CVCs. Our results
suggest that, in selected ICU patients at higher central
vein puncture risk, using AST-CVCs and the GWX
method carries similar risks of subsequent line coloni-
zation with pathogens and CA-BSI as NI-CVCs. Survi-
val to both hospital and ICU discharge were also
similar for both groups.
Previous studies
GWX might increase the risk of catheter-related infec-
tions [30-32]. However, previous studies did not adjust
for all relevant confounders or report how GWX was
performed. Moreover, current guidelines on GWX [33]
are based on data from studies published in the 1990s.
In the most prominent of these studies [7], the GWX
procedure was often performed with insertion via the
most distal port and distal to the CVC hub (Sawyer R
and Peled H, personal communication). In 2000, on the
basis of such information, a review concluded that
GWX might be associated with a higher rate of catheter
colonisation and catheter-related bacteraemia [13]. In
addition, recent guidelines [33] imply that GWX would
be the final step in the therapeutic process for a sus-
pected CVC-related infection.
In contrast to the above positions, several other obser-
vational studies reported that GWX of a CVC was
microbiologically safe [11,15,30,34]. Unfortunately, in
the absence of randomized trials or contemporaneous
controls, these reports were confounded by selection
bias and provided only weak evidence for or against
GWX-CVCs. In the last 10 years, only two studies have
assessed the potential relationship between GWX and
microbiological outcome. One [15] reported a rate of
Table 2 Microbiological outcomes
Controls GWX group P-value
No. of patients who had blood cultures taken 121 (74%) 106 (73%) 0.83
No. of positive peripheral blood culture results 31 (26%) 26 (25%) 0.85
No. of line tips cultured 95 (58%) 85 (56%) 0.78
No. of cultured line tips growing pathogens among patients where CVC tip was sent for culture 6 (6.3%) 5 (5.9%) 0.90
No. of patients with same organism in blood culture and line tip 3 (1.8%) 2 (1.4%) 0.77
CVC, central venous catheter
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colonization for newly inserted CVCs of 6.8% compared
with 2.3% for GWX CVCs. No information was pro-
vided on the technique of GWX. The other found that
GWX was associated with an increased risk of catheter-
related bacteraemia [35]. However, this latter study only
assessed 76 CVCs inserted by GWX, with only half
being triple lumen CVCs. Moreover, one-third was
inserted outside the ICU, chlorhexidine preparation of
the site was only used in less than 10% of insertions,
and AST-CVCs were not used. Additionally, in contrast
to our study, the process of GWX insertion was not
described.
Implications of study findings
The results of our study suggest that, when using AST-
CVCs and a sterile procedure for insertion of the guide
wire below the hub and directly into the AST catheter,
CVC replacement by GWX in the ICU is likely micro-
biologically equivalent to de novo CVC insertion. The
information obtained in our study justifies the use of
GWX as an acceptable approach to CVC replacement in
selected ICU patients deemed at high risk from
attempted central vein puncture because of coagulopa-
thy, thrombocytopenia and/or anatomical characteristics
(for example, extreme obesity, poor central vein visuali-
zation on ultrasound), provided that AST CVCs are
used and a sterile technique with insertion of the wire
below the hub is applied and there is no evidence of
insertion site inflammation. It must be emphatically sta-
ted, however, that, if the line exchanged by the guide
wire is found to be colonized, the GWX CVC must then
be removed and a new CVC inserted at another site.
Strengths and limitations
This study has several strengths. It describes the largest
cohort of GWX CVCs in the literature. It is the first to
assess the microbiological outcome of GWX of AST-
CVCs and to explicitly present the technique of GWX
in detail. Nonetheless, our database provided only infor-
mation on the admission diagnosis but not on the pre-
sence, degree and alternative sources of sepsis at the
time of CVC removal. These shortcomings applied to
both cohorts similarly, making the introduction of bias
in favour or against GWX unlikely.
Our study compared microbiological outcomes and
major clinical outcomes with those of contemporaneous
newly inserted CVCs. However, the comparison with
new CVCs inserted early in the course of the ICU
admissions in a cohort of patients with a relatively short
stay biased the study against GWX-CVCs. The fact that,
despite such negative bias, there was no evidence of
greater colonization rates after GWX supports the
notion that GXW insertion of AST-CVCs is likely
microbiologically similar to newly inserted CVCs.
Our study data were obtained from the ICU and
microbiology databases. These were collected prospec-
tively and electronically recorded and were not amen-
able to manipulation or post-hoc ascertainment bias.
The study period was long, allowing the capture of data
from many different clinicians (junior and senior),
which suggests a degree of generalizability. However,
our study was retrospective with all the inherent limita-
tions associated with such design. Of technical impor-
tance, we applied a specific technique to GWX as
illustrated in the figures. This technique may have
decreased the risk of colonization. Unfortunately, all
previous papers describing the microbiological outcome
of GWX failed to report the details of the GWX
technique.
Our findings are from an intensive care unit, which
serves as a referral centre for liver transplantation and
which, therefore, handles many immune-suppressed
patients with advanced liver disease and coagulopathy,
who require CVCs for extended periods and are at high
risk of bleeding. Thus, our results may not apply to dif-
ferent patient populations. We acknowledge that CVC
insertion in higher risk patients may still be safe under
ultrasound guidance. However, logically the avoidance
of puncture and dilatation must provide a greater degree
of safety.
The rates of CA-BSI appear slightly higher than those
reported in a recent multicentre study [29]. However,
the study population had twice our unit average stay
among controls and six times the unit average among
GWX patients. Our ICU applied all components of the
bundle of line insertion care [29] during the entire study
period in a strategic attempt to decrease noscomial
infection associated with any cannulation in complex
patients [36,37].
Our findings could represent a type II error. However,
ours is the largest cohort of patients receiving GWX of
CVC where all catheters in question were triple lumen
AST-CVCs catheters. Finally, the point estimate for line
colonization with pathogens and CA-BSI was lower in
the GWX cohort despite the illness duration related bias
against them. Thus, within these statistical limitations,
our study provides initial evidence for clinicians to esti-
mate the microbiological risk of GWX insertion of
CVCs in selected patients at higher risk of central vein
cannulation.
Conclusions
In conclusion, GWX of an antimicrobial surface treated
CVC in selected patients at high risk from central vein
cannulation appears not to be associated with an
increased rate of bacteraemia or pathogen colonization
compared with a newly inserted CVC. Such GWX of a
CVC is safe and easy to perform. Treatment of
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suspected CVC-related sepsis should include antibiotics
and removal of the CVC. However, if the CVC needs
replacement, in selected patients with severe coagulopa-
thy or unfavourable anatomy or limited availability of
other insertion sites, clinicians may now consider GWX
using an AST-CVC with a clearer appreciation of its
microbiological risk.
Key messages
• In selected patients, central venous catheter repla-
cement by guide wire exchange is microbiologically
associated with a low rate of line-related bacteraemia
when using antimicrobial surface-treated catheters.
• In selected patients, guide wire exchange of central
venous catheters can be technically performed in a
systematic way that minimizes risk of colonization.
• In selected patients at high risk of bleeding or with
anatomically unfavourable characteristics, replace-
ment of a new central venous catheter by guide-wire
exchange may be a safe and preferred approach
when antimicrobial surface treated catheters are
used.
• If the CVC removed by GWX is found to have
been colonized, however, the CVC inserted by GWX
must be removed and a new CVC must be inserted
at another site.
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